QUOTE AND NEWS
StreetInsider.com  Jul 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Incyte+%28INCY%29+Jakafi+Receives+FDA+Approval+for+Expanded+Labeling/9692925.html for the full story.
Market Intelligence Center  Jul 25  Comment 
The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center are highlighting two trades on Incyte (INCY) today after it closed at $47.95 on Thursday. For more conservative investors, look...
newratings.com  Jul 8  Comment 
BASEL (dpa-AFX) - Incyte Corp. (INCY) announced Tuesday that it has earned a $25 million milestone payment from Novartis (NVS) in connection with the approval of Jakavi (ruxolitinib) in Japan for the treatment of patients with myelofibrosis....
StreetInsider.com  Jul 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Incyte+%28INCY%29+Reaches+%2425M+Milestone+in+Novartis+%28NVS%29+Collaboration/9643689.html for the full story.
Motley Fool  Jul 7  Comment 
Both stocks have been long-term double-digit gainers.
Market Intelligence Center  Jun 26  Comment 
Incyte (INCY) presents a trading opportunity that offers a 6.75% return in just 86 days. A covered call on Incyte at the $55.00 level expiring on Sep. '14 offers an assigned return rate of 6.75% or 28.67% annualized. This trade offers 8.36%...
Motley Fool  Jun 24  Comment 
Geron gets a clinical hold released, but is still a ways away from competing with Incyte's Jakafi.
TheStreet.com  Jun 11  Comment 
NEW YORK (TheStreet) -- Incyte has been a source of investor contention since the company first announced Jakafi was effective in increasing overall survival in pancreatic cancer patients. The controversy centered on Incyte's analysis, which...
DailyFinance  Jun 3  Comment 
Incyte Corporation (Nasdaq: INCY) today announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera (PV). Ruxolitinib, compared to best...
Benzinga  Jun 3  Comment 
Incyte Corporation (Nasdaq: INCY) today announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera (PV). Ruxolitinib, compared to best available therapy...




 

Incyte Corporation (NYSE: INCY) is a Wilmington, DE-based drug discovery and development company with a focus on oral compounds to treat HIV, inflammation, cancer, and diabetes. The company has transformed from a genomic-based information supplier to a fully integrated drug discovery and development organization. The company's lead internal compound, Ruxolitinib, has completed phase III clinical trials for the treatment of myelofibrosis and submitted an NDA application to the FDA in June of 2011.

The ability of Incyte to push its lead compounds through regulatory approval and to maintain the cash required to do so will impact Incyte Corporation's long-term success.

Business Growth[1]

In 2010, total revenues for Incyte were $170 million, reflecting milestone payments received from drug development partners. These milestone payments include $50 million from Novartis AG (NVS) for the initiation of the RESPONSE clincal trial, $49 million from Eli Lilly and Company (LLY) for two early stage drugs, and $67 million in amortized payments made earlier by the two partner companies.

Net loss for 2010 was $31.8 million, down from a 2009 net loss of $212 million.

Pipeline[2][3]

  • Ruxolitinib: Incyte's flagship product, Ruxolitinib is currently in two Phase III studies, COMFORT and RESPONSE to study its use as a treatment for myelofibrosis and polycythemia vera, two rare diseases without current approved treatments. The COMFORT trial has been completed and Incyte submitted an NDA application to the FDA in June of 2011.[4] The RESPONSE trial began in the fourth quarter of 2010. Ruxolitinib is also involved in Phase I and II trials to treat leukemia and other blood-based diseases.[5]
  • Sheddase Inhibitors: Incyte is developing INCB7839 to treat Her-2 positive breast cancer. Phase II trials have been completed and Incyte will decide whether to progress to Phase III trials.

Trends and Forces

Incyte Needs to Obtain Regulatory Approval in Order to Earn Significant Revenue

To date, all of Incyte's revenue has been earned from milestone payments paid by pharmaceutical partners for the development of its flagship product, Ruxolitinib. In order to make the full transition from a development-stage company to a fully commercial pharmaceutical company, Incyte needs to obtain regulatory approval for its drugs. Incyte submitted an NDA application for the use of Ruxolitinib to treat myelofibrosis in 2011 and will receive a response from the FDA in late 2012 or early 2013. The outcome of that response will profoundly impact Incyte's valuation.[6]

Cash on Hand will Impact Incyte's Ability to Maintain Operations

In the absence of organic revenue, Incyte is reliant on its cash on hand to fund ongoing operations. As of the end of 2010, Incyte had $418 million in cash.[7] In 2011, Incyte expects to cash use to range between $185 and $200 million.[8] Incyte's ability to maintain positive cash as it develops its lead products will impact its ability to bring these drugs to market and develop a revenue stream of its own.

Competition

Ruxolitinib belongs to a class of drugs called Jak inhibitors. The following companies are developing drugs within this class:

  • YM BioSciences (YMI): Developing a Jak inhibitor for myelofibrosis that could be a direct competitor to Ruxolitinib. YM BioSciences' drug is in Phase II clinical trials.[9]
  • Sanofi-Aventis SA (SNY): In 2010, Sanofi-Aventis purchased TargeGen, whose flagship drug is a Jak inhibitor being developed to treat myelofibrosis.[10]

References

  1. Incyte Reports 2010 Financial Results; Provides 2011 Key Objectives And Financial Guidance
  2. INCY 2011 10K
  3. Incyte Product Pipeline
  4. Incyte Submits NDA For Ruxolitinib For Rare Blood Cancer
  5. Incyte Corporation's CEO Discusses Q1 2011 Results- Earnings Call Transcript
  6. Incyte Corporation's CEO Discusses Q1 2011 Results- Earnings Call Transcript
  7. INCY 2011 10K
  8. Incyte Reports 2010 Financial Results; Provides 2011 Key Objectives And Financial Guidance
  9. Incyte and YM Biosciences in Race to Market Strongest JAK Inhibitor
  10. On a spree, Sanofi scoops up TargeGen in $635M Deal
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki